Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis

This study provides Class IV evidence on the safety, pharmacokinetics, and immune effects of an mAb to CD40L in patients with RRMS.

Source: Neurology Neuroimmunology and Neuroinflammation - October 15, 2021 Category: Neurology Authors: Fadul, C. E., Mao-Draayer, Y., Ryan, K. A., Noelle, R. J., Wishart, H. A., Channon, J. Y., Kasper, I. R., Oliver, B., Mielcarz, D. W., Kasper, L. H. Tags: All Immunology, Autoimmune diseases, All Clinical Neurology, All Clinical trials, Multiple sclerosis Article Source Type: research